Codexis, Inc. (CDXS)
NASDAQ: CDXS · Real-Time Price · USD
1.480
-0.510 (-25.63%)
At close: Jul 24, 2026, 4:00 PM EDT
1.450
-0.030 (-2.03%)
After-hours: Jul 24, 2026, 7:59 PM EDT
Company Description
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Codexis, Inc.
| Country | United States |
| Founded | 2002 |
| IPO Date | Apr 22, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 146 |
| CEO | Alison Moore |
Contact Details
Address: 200 Penobscot Drive Redwood City, California 94063 United States | |
| Phone | 650 421 8100 |
| Website | codexis.com |
Stock Details
| Ticker Symbol | CDXS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001200375 |
| CUSIP Number | 192005106 |
| ISIN Number | US1920051067 |
| Employer ID | 71-0872999 |
| SIC Code | 2860 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alison Moore Ph.D. | President, Chief Executive Officer and Director |
| Georgia L. Erbez | Chief Financial Officer and Chief Business Officer |
| Dr. Stefan Lutz Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 24, 2026 | 424B5 | Filing |
| Jul 23, 2026 | 424B5 | Filing |
| Jul 23, 2026 | 8-K | Current Report |
| Jul 20, 2026 | SCHEDULE 13G/A | Filing |
| Jun 22, 2026 | 8-K | Current Report |
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| May 5, 2026 | SCHEDULE 13G/A | Filing |
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |